Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat <i>Clostridium difficile</i> infection in France

Abstract

This study demonstrated that, despite higher acquisition costs, the lower recurrence rate with fidaxomicin resulted in cost savings or low incremental costs compared with vancomycin.